www.fool.com
2026-06-01
This article explores whether pharmaceutical giant Eli Lilly is beginning a Nvidia-style growth trajectory. Nvidia has delivered explosive revenue growth in the AI chip market, with its stock rising over 400% in the past three years. Similarly, Lilly is gaining momentum in the rapidly expanding weig